CSIMarket
 
Evotec Se  (NASDAQ: EVO)
Other Ticker:  
 
 
Price: $4.2200 $0.01 0.238%
Day's High: $4.22 Week Perf: 16.25 %
Day's Low: $ 4.04 30 Day Perf: 16.25 %
Volume (M): 21 52 Wk High: $ 5.68
Volume (M$): $ 88 52 Wk Avg: $4.18
Open: $4.09 52 Wk Low: $2.84



 Market Capitalization (Millions $) 747
 Shares Outstanding (Millions) 177
 Employees 2,200
 Revenues (TTM) (Millions $) 875
 Net Income (TTM) (Millions $) -94
 Cash Flow (TTM) (Millions $) 465
 Capital Exp. (TTM) (Millions $) 239

Evotec Se
Evotec SE is a publicly-traded German biotechnology firm operating in the pharmaceutical and drug discovery industry. The company is headquartered in Hamburg, Germany, and has various locations and offices worldwide.

Evotec SE is primarily engaged in the development and discovery of drugs, which includes providing comprehensive solutions for the pharmaceutical industry. The company works with leading biopharmaceutical companies, academic institutions, and disease foundations, focusing on providing innovative solutions through collaborations and partnerships.

Founded in 1993, the company has over the years been focused on research and development, cutting-edge technologies and collaboration, drug discovery, and strategic partnerships. The company has built a reputation as a leading provider of high-value drug discovery services, particularly in the fields of neuroscience, oncology, and autoimmune diseases.

Their technology platform, called the "Evotec Operating System," integrates different lab technologies and data management capabilities, enabling high-throughput screening and drug identification. This platform has been instrumental in the company's success as it enables them to work collaboratively and efficiently in the drug discovery process.

Evotec SE's services range from target identification, validation, and optimization to drug screening, hit identification, and preclinical development. The company also offers customized solutions tailored for specific client needs and has several programs in clinical and pre-clinical stages of development.

Additionally, Evotec SE has an extensive drug development pipeline, which includes both proprietary programs as well as partnered programs. To date, the company has over 100 partners across the globe and an impressive portfolio of drug candidates.

In terms of financials, Evotec SE has been consistent in its revenue growth, with a revenue increase of 17% in 2020 compared to the previous year. As of mid-2021, the company reported a total of over 4,000 employees worldwide, showing significant growth and expansion over the years.

Overall, Evotec SE has established itself as a leading biotech company that leverages cutting-edge technologies, strategic partnerships, and collaboration in drug discovery and development. With a proven track record, a robust pipeline, and consistent growth, the company is well-positioned to continue making significant strides in the biotech industry.


   Company Address: Essener Bogen 7 Hamburg 22419
   Company Phone Number: 40 560810   Stock Exchange / Ticker: NASDAQ EVO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CTLT        0.38% 
CYRX        0.38% 
VRTX        4.02% 
BRAG        4.02% 
CRL        11.67% 
OABI        11.67% 
• View Complete Report
   



Medicure Inc

Breaking down fourth quarter of 2024 performance, MPHs' experienced that revenue went up modest

For the most recent fiscal period Medicure Inc increased a deficit per share of $-0.08 per share compare to $-0.07 a year before and from $0.00 per share from the prior financial reporting period. The Revenue grew gently by 0.982 % to $16.78 million from $16.62 million in the same financial reporting period a year before and sequentially from $0.00 million. To put company's fourth quarter of 2024 behavior, we should analyze the on averageMajor Pharmaceutical Preparations sectors, it is apparent, that Major Pharmaceutical Preparations company has come in short of as the peers statement business growth of 11.85% from the same financial reporting period a year ago.

Viking Therapeutics Inc

VKTX, deterioration in the company performance during the financial span ending first quarter of 2025

Following the big players in the Major Pharmaceutical Preparations industry, a number of lesser known companies are publishing their numbers. VKTX revealed it has booked operating loss of $-55.469 million, for the first quarter of 2025.

Johnson And Johnson

A restrained Top-line improvement at the company in the first quarter of 2025 earnings season

Johnson And Johnson delivered astonishing bottom-line growth on slow Revenue improvement in the first quarter of 2025 earnings season, where earnings per share grown rapidly by 238.81 % at $4.54 per share, revenue rose moderate by 2.385 % to $21.89 billion from the similar quarter a year before. To insertJNJs' first quarter of 2025 behavior, the investors need to analyze the remainder ofMajor Pharmaceutical Preparations sectors, it is clear, that JNJ has under achieved as the peers announcement revenue growth of 3.58% relative to the similar period a year ago.

Bristol Myers Squibb Company

Soft Top-line at Bristol Myers Squibb Company in the most recent fiscal period

For the first quarter of 2025 earnings season Bristol Myers Squibb Company profitability turned positive of $1.20 per share compare to $-5.89 a year prior and EPS grown rapidly by 3319.05 % from $0.04 per share from the preceding quarter. The revenue sunk by -5.596 % to $11.20 billion from $11.87 billion in the similar quarter a year prior and sequentially Revenue deteriorated by -9.245 % from $12.34 billion. The deterioration of revenue is relative to relative to all in all Major Pharmaceutical Preparations industry, which recorded a top-line improvement during the same period.

Unity Biotechnology Inc

The Major Pharmaceutical Preparations company added some great scenario for the investors, presenting a relevant growth in January to March 31 2025 with operating shortfall of $-6.891 million

The investors have not assumed any adjustments at the revenue throughout the the January to March 31 2025 reporting cycle at the UBX. But, they pay very near attention to the company's operating shortfall which came in at $-6.891 million, in the same period.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com